Conference Call with Supriya Lifescience Manhttps://youtu.be/CvlNlXdt8Ksagement and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.
Conference Call with Supriya Lifescience Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Supriya Lifescience declares Q3FY22 result: Consolidated Revenue for Q3FY22 reported a growth of 44 % (YoY) to Rs. 1,224.4 million as compared to Rs. 850.2 million in Q3FY21. The current quarter performance was driven by very strong demand for anaesthetic, Antiasthmatic and Vitamin therapy. The company expects the demand for these therapies to be strong, also expect demand for antihistamine to pick up going forward. Increase in Q3 sales was also driven by higher penetration in regulated markets like Europe and Latin America Gross Profit for Q3 FY22 stood at Rs. 806.5 million as compared to Rs. 522.7 million in Q3 FY21 , a growth of 54% compared to same quarter last year. EBITDA for Q3 FY22 stood at Rs. 438.2 million and EBITDA Margin stood at 36% as against Rs. 301.6 million in Q3 FY21 (35%), registering a growth of 45% (YoY) PAT for Q3 FY22 stood at Rs. 396.4 million and PAT Margin stood at 32 % in Q3 FY21 as against Rs. 156.9 million in Q3FY21, registering a growth of 153%. Commenting on the Results, Dr. Satish Wagh, Chairman & Managing Director, Supriya Lifescience said, “I would like to thank everyone for the overwhelming support we have received for our IPO. With this support and trust from the investors our IPO was oversubscribed by 71.47 times. The company has shown consistent performance for 9 months FY22 with an operating revenue of Rs 3,525.0 Mn with EBIDTA of Rs 1,424.8 Mn (40 % of Revenue) and PAT of Rs 1,056.0 Mn (30% of revenue). The current quarter performance was driven by very strong demand for anaesthetic, antiasthmatic and Vitamin products. The fourth manufacturing block at our site got operational in May’21. We have also commenced the work for the next manufacturing block which is expected to get operational by FY23. This block will add 310 KL capacity. Two new warehouses for Finished Goods and Raw materials will get operational by Q1 FY23. A new Quality Control laboratory along with state-of-the-art R&D; laboratory will be operational by Q2 FY23. In line with company strategy to penetrate in more regulated markets, we have also applied for registering more products in US, European and Chinese markets “ Result PDF